We’re thrilled to share that out of many exceptional applications, NaDeNo achieved the highest evaluation scores from the prestigious PHOENIX OITB Open Call initiative! This recognition underscores the strength of our proprietary nanoparticle technology and the impact it promises for cancer therapy
Thanks to this achievement, we now gain access to PHOENIX OITB comprehensive nanopharmaceutical development services, including advanced GMP manufacturing, regulatory expertise, and cutting-edge characterization tools.

These resources will accelerate the path to clinical trials, reducing both cost and time. This milestone demonstrates that NaDeNo’s platform isn’t just innovative—it’s validated by global leaders in nanomedicine. It’s an exciting time as we continue driving life-changing cancer treatments closer to patients.